StreetAlpha.app
Home › Stocks › ARGX

Argenx SE (ARGX)

Healthcare
$947.52
▼ −0.36%
LAST CLOSE · NOV 17

argenx develops antibody medicines for autoimmune and neuromuscular diseases, with its main product VYVGART. It last closed at $947.52 on Nov 17, down 0.36% on the day. The average 12-month price target from 9 analysts is $1176.33 (+24.1% from the last close), with a high of $1400.00 and a low of $861.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (8 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 6 whale options trades in ARGX, 33% of them bullish and 67% bearish. In the past 30 days there were 6 dark pool prints totaling $9.7M, the largest $2.6M.

AI Auto Pilots
Is ARGX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$1.3B
+55.1% vs a year ago
Free cash flow
$679.0M
Balance sheet
Cash & equivalents
$3.5B
At Dec 31
Shareholder equity
$7.3B
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$408.3M−$408.3MFY2021FY2022: −$709.6M−$709.6MFY2022FY2023: −$295.1M−$295.1MFY2023FY2024: $833.0M$833.0MFY2024FY2025: $1.3B$1.3BFY2025

From ARGX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 19). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
8 Buy1 Hold0 Sell
Each firm's latest rating on ARGX in the past 90 days
Average 12-month target
$1176.33
▲ 24.1% upside

Based on 9 analysts who set a price target on ARGX in the past 90 days. The average target is $1176.33, with a high of $1400.00 and a low of $861.00, compared with the last close of $947.52.

Low $861.00Avg $1176.33High $1400.00
Blue marker: last close $947.52
Highest target$1400.00
Average target$1176.33
Lowest target$861.00
Latest rating changes
Piper SandlerTarget raised
Nov 16Buy$1215 → $1350
Morgan StanleyTarget lowered
Nov 13Buy$1190 → $1130
CitigroupTarget raised
Oct 27Buy$1182 → $1232
Morgan StanleyTarget lowered
Oct 23Buy$1250 → $1190
Wells FargoTarget lowered
Oct 23Buy$1356 → $1336
DateFirmActionRatingPrice target
Nov 16Piper SandlerTarget raisedBuy$1215 → $1350
Nov 13Morgan StanleyTarget loweredBuy$1190 → $1130
Oct 27CitigroupTarget raisedBuy$1182 → $1232
Oct 23Morgan StanleyTarget loweredBuy$1250 → $1190
Oct 23Wells FargoTarget loweredBuy$1356 → $1336
Loading…

Technical Analysis

ARGX · as of the Nov 17 close · updated after every close
Uptrend

The stock is 3% above its 20 day and 3% above its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot at $944.85, and the nearest resistance the swing high (Jul 2) at $953.58.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 2.9%/day
Key levels
$1072.7552 week high+13.2%
$955.04Pivot R1+0.8%
$953.58Swing high (Jul 2)+0.6%
$947.52Last close
$944.85Pivot−0.3%
$937.33Pivot S1−1.1%
$934.19Swing low (Sep 23)−1.4%
$924.43100 day average−2.4%
$921.0550 day average−2.8%
$917.7320 day average−3.1%
$861.39200 day average−9.1%
$661.8552 week low−30.1%
Indicators
RSI (14)55.71Middle of its rangeNeutral
MACD17.44Above its signal lineBullish
Stochastic70.1Middle of its rangeNeutral
ADX (14)20.3Weak trend
Williams %R-35.6Oversold below −80, overbought above −20Neutral
CCI (20)56.6Oversold below −100, overbought above 100Neutral
Rate of change+5.2%Change over 10 sessionsBullish
ATR (14)$27.94Typical daily range, 3.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ARGX

What happened before

See how ARGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish2 bullish and 4 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow ARGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
6
Bullish
2
33%
Bearish
4
67%
Date span
Aug 28 – Oct 6
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$9.7M
Largest print
$2.6M
Loading…

ARGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲313 buying vs 188 selling
  • ▼Shares held by funds -1.7%
  • ▲Funds holding +39
  • ▲Superinvestors: 4 added, 0 cut
  • ▼Put/call 0.14 to 0.74
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding551512+7.6%
In funds' top 101413+7.7%
Held by funds–––
New / increased90 / 22380 / 180+20.4%
Reduced / sold out140 / 48163 / 50−11.7%
Put/call ratio0.740.14+427.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARGX is in one of them and how their past ARGX trades turned out.

ARGX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARGX in an article yet. Here's the latest on the wider market.

ARGX Congress Trades

All congress trades →
Trades, 12 months
4
Buys
4
100%
Sells
0
0%
People
2
Last filed Nov 10
Who traded ARGX · since 2023
Latest 5 filings of 6
$1K – $15KTraded Oct 27, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 15, 2026Filed Nov 10, 2026
$15K – $50KTraded Oct 14, 2026Filed Nov 10, 2026
$1K – $15KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Feb 11, 2025Filed May 14, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KOct 27, 2026Nov 10, 202614 d
Gilbert CisnerosD · CABuy$1K – $15KOct 15, 2026Nov 10, 202626 d
Gilbert CisnerosD · CABuy$15K – $50KOct 14, 2026Nov 10, 202627 d
Alan ArmstrongHouseBuy$1K – $15KMar 30, 2026Jul 21, 2026113 d
Sean DuffyExecutive branchSell$1K – $15KFeb 11, 2025May 14, 202592 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Argenx SE

argenx is a biopharmaceutical company that develops antibody medicines for autoimmune and neuromuscular diseases. Its main product, VYVGART, is approved for several conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The company sells its medicines to patients and works with healthcare professionals, and it is developing a range of other candidates in clinical trials. It is based in Zwijnaarde.

Headquarters
Zwijnaarde